JPMorgan Global Growth & Income

JPMorgan Global Growth & Income (JPGI, formerly JPMorgan Overseas IT) aims to achieve capital growth from world stock markets, by holding a diversified portfolio of investments in which the portfolio manager has a high degree of conviction. Following a change in its distribution policy in July 2016, it also aims to pay a dividend equivalent to at least 4% of NAV at the preceding year-end, announced at the start of the year to give visibility of income.

Price Performance
%	1M	3M	12M
Actual	(2.1)	2.6	6.7
Relative	1.3	2.8	5.4
52 week high/low	479.0p/395.5p

12M

Actual

(2.1)

2.6

6.7

Relative

1.3

2.8

5.4

52 week high/low

479.0p/395.5p

Equities

Equities by Sector

Sectors

Thematics

Latest

Healthcare-focused trusts: A sector on the mend

MediaWatch – One step forward, two steps back

ConsumerWatch – Don’t look down

Audiovisual

Latest

Recce Pharmaceuticals – executive interview

VEON – executive interview with CFO Joop Brakenhoff

VEON – executive interview with CEO Kaan Terzioğlu

About Edison

About Edison

Careers

JPMorgan Global Growth & Income (LSE: JGGI)

Latest Insights

JPMorgan Global Growth & Income — Income and outperformance in uncertain times

JPMorgan Global Growth & Income — JPM Elect merger strengthens investment case

JPMorgan Global Growth & Income — Stock selection skills delivering strong performance

JPMorgan Global Growth & Income — Merger with SCIN will double size and cut charge

Share Price Performance

Financials

Research

JPMorgan Global Growth & Income — Strong long-term capital growth

JPMorgan Global Growth & Income — Value-focused growth fund with 4% distributions

JPMorgan Global Growth & Income — Sharper focus on quality under new managers

Executive interview – JPMorgan Global Growth & Income

JPMorgan Global Growth & Income — Strong outperformance from focused global fund

JPMorgan Global Convertibles Income Fund — Update 27 September 2016

Banco Angolano de Investimentos (BAI) – Money-centre bank with lending optionality

The art of measurement – Challenges in metrology

Vietnam Holding – Vietnam in the global digital race

US small-cap equities – Time to shine?

MediaWatch – Encouragements and frustrations

ConsumerWatch – The times they are a-changin’

Emerging markets – Worthy of consideration

Dynam Capital at the 2024 Vietnam ESG Conference

MediaWatch – Glimpses of positivity

ConsumerWatch – Give me a reason to love you

UK stock market – Scope for further upside in UK large-cap stocks

Listed private equity – Performing a balancing act

ConsumerWatch – At least someone loves me

MediaWatch – Rinse and repeat

Outlook for 2024: Life sciences – where has the conviction gone?

South African life assurers: Where is the growth?

Deutsches Eigenkapitalforum (EKF) 2023 consumer and media

Deutsches Eigenkapitalforum (EKF) 2023 technology

Deutsches Eigenkapitalforum (EKF) 2023 financials and investment companies

Deutsches Eigenkapitalforum (EKF) 2023 industrials

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

VolitionRx – Decoding the DNA of cancer

MediaWatch – Still waiting…

ConsumerWatch – Falling into the fall

Shades of the 1970s

The long and winding road

MediaWatch – Targeting the opportunities

ConsumerWatch – Making the most of the summer

ASCO 2023 key takeaways

IFRS 17: Impact on life assurance companies

MediaWatch – Vision On

ConsumerWatch – A Spring in the step

Quantum computing: A booming industry

Critical minerals: The investment vacuum

Crypto, are you dead yet?

UK housebuilders

European equities

Listed Private Equity

Lithium’s adolescence

Battery energy storage

MediaWatch – Screening well

Vietnamese equities: Due a comeback?

Machine learning in drug development

ConsumerWatch – January sales

Outlook for 2023: Biotechs remain central to novel drug development

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

Cell and gene therapies

Investment companies: Latin America is worthy of consideration

Drug delivery platforms